| DC9335 |
AT7867
Featured
|
AT7867 is a potent ATP-competitive inhibitor of Akt1/2/3 and p70S6K/PKA with IC50 of 32 nM/17 nM/47 nM and 85 nM/20 nM, respectively; little activity outside the AGC kinase family. |
|
| DC7070 |
AT9283
Featured
|
AT9283 is a small molecule a multi-targeted inhibitor with of 4, 1.2, 1.1 and approximate 3 nM for Bcr-Abl(T3151), Jak2 and Jak3, aurora A and B, respectively. |
|
| DC11889 |
Atabecestat
Featured
|
Atabecestat (JNJ-54861911, JNJ54861911) is a novel potent, oral beta-secretase (BACE) inhibitor for treatment of Alzheimer's Disease. |
|
| DC21121 |
Ataciguat
Featured
|
Ataciguat (HMR-1766) is a potent, specific soluble guanylate cyclase (sGC) activator with EC50 of 0.51 uM, preferentially activates the NO-insensitive heme-oxidized form of sGC. |
|
| DC3150 |
Atazanavir
Featured
|
Atazanavir is a HIV protease inhibitor with Ki of 2.66 nM. |
|
| DC7365 |
ATB-346
Featured
|
ATB-346 is a novel hydrogen sulphide-releasing derivative of naproxen with markedly reduced toxicity. |
|
| DC7366 |
Atglistatin
Featured
|
Atglistatin is a highly potent, selective and competitive inhibitor of adipose triglyceride lipase (ATGL) with an IC50 of ~0.7 μM for inhibition of lipolysis in vitro, but no toxicity up to a concentration of 50 μM. |
|
| DC10921 |
ATH686
Featured
|
ATH686 (ATH-686) is a potent and selective, second-generation inhibitor of mutant FLT3 protein kinase. |
|
| DC8925 |
Atipamezole
Featured
|
Atipamezole(MPV1248) is an alpha-adrenoceptor antagonist with high affinity and selectivity for the alpha 2-receptor. |
|
| DC7709 |
ATN-161
Featured
|
ATN-161 is a novel integrin α5β1 antagonist, which inhibits angiogenesis and growth of liver metastases in a murine model. |
|
| DCAPI1442 |
Atorvastatin Calcium
Featured
|
Atorvastatin Calcium |
|
| DCAPI1390 |
Atovaquone (Atavaquone)
Featured
|
Atovaquone is a medication used to treat or prevent for pneumocystis pneumonia, toxoplasmosis, malaria, and babesia. |
|
| DC23072 |
Atractylenolide II
Featured
|
Atractylenolide II has antiinflammatory activity, it can inhibit platelets activities and thrombus formation. Atractylenolide II has cytotoxic/apoptotic effects may via p38 activation ,ERK and Akt inactivation, p53 dependent, it also has antimelanoma effe |
|
| DC23073 |
Atractylenolide III
Featured
|
Atractylenolide III, a potential house dust mite control agent, has neuroprotection, gastroprotective, anti-cancer, and anti-inflammatory activities, it also may control immunological reactions by regulating the cellular functions of IL-6 in mast cells. |
|
| DC23059 |
Atractylon
Featured
|
Atractylone has inhibitory effects on mast cell-mediated allergic reactions, it regulates the degranulation of mast cell, proves its potential in the treatment of mast cell-mediated allergic reactions. |
|
| DCAPI1288 |
Atracurium besylate
Featured
|
Atracurium besylate is a non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents. |
|
| DC10018 |
Atrasentan hydrochloride
Featured
|
Atrasentan Hcl(A-147627) is an endothelin antagonist receptor (IC50=0.0551 nM, ETA) being developed for the treatment of prostate cancer. |
|
| DC10552 |
AU1235
Featured
|
AU1235 is an adamantyl urea inhibitor of Mycobacterium tuberculosis. |
|
| DC21865 |
Aumitin
Featured
|
Aumitin is a novel potent autophagy inhibitor with IC50 of 124 and 244 nM against starvation- and rapamycin- induced autophagy respectively, targets mitochondrial complex I. |
|
| DC12428 |
AUNP-12
Featured
|
AUNP-12 (Aurigene-012) is a PD-1 inhibitor peptide, blocks the PD-1/PD-L1, PD-1/PD-L2 and PD-L1/CD80 pathways. |
|
| DC10138 |
Auristatin E
Featured
|
Auristatin E is a cytotoxic tubulin modifier with potent and selective antitumor activity; MMAE analog and cytotoxin in Antibody-drug conjugates. |
|
| DC7964 |
Aurora A Inhibitor I
Featured
|
Aurora A inhibitor I is a selective Aurora A inhibitor (Aurora A: IC50=0.0034 μM; Aurora B IC50=3.4 μM), (B/A ratio=1000). |
|
| DC26118 |
AKI-7169(Aurora Kinase Inhibitor III)
Featured
|
Aurora kinase inhibitor III is a potent inhibitor of Aurora A kinase (IC50 = 42 nM). |
|
| DC11999 |
AUT-1
Featured
|
AUT-1 is a novel specific, cell permeant modulator of Kv3 channels with EC50 of 4.7 and 4.9 uM for Kv3.1b and Kv3.2a, respectively. |
|
| DC10548 |
Auten-99
Featured
|
Auten-99 is a novel inhibitor of the myotubularin phosphatase Jumpy (also called MTMR14), acrossing the blood-brain barrier and exerting potent neuroprotective effects. |
|
| DC10461 |
Autophinib
Featured
|
Autophinib is a novel potent autophagy inhibitor, inhibiting autophagy induced by starvation or Rapamycin by targeting the lipid kinase VPS34. |
|
| DC5202 |
Luminespib (NVP-AUY922)
Featured
|
AUY922 (NVP-AUY922) is a highly potent HSP90 inhibitor for HSP90α/β with IC50 of 13 nM /21 nM, weaker potency against the HSP90 family members GRP94 and TRAP-1, exhibits the tightest binding of any small-molecule HSP90 ligand. Phase 1/2. |
|
| DC8799 |
Avanafil(TA-1790)
Featured
|
Avanafil(TA-1790) is a potent and highly selective phosphodiesterase-5(PDE-5) inhibitor(IC50=5.2 nM) for erectile dysfunction; lower selectivity against PDE1, PDE6, and PDE11. |
|
| DC1094 |
Avasimibe
Featured
|
Avasimibe inhibits ACAT and CYP2C9 with IC50 of 3.3 μM and 2.9 μM, respectively. |
|
| DC10732 |
Anavex-2-73 free base (Blarcamesine)
Featured
|
AVex-73 is a muscarinic M1 agonist potentially for the treatment of Alzheimer's disease |
|
